Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the formation of the Company’s Scientific Advisory Board (SAB) with four esteemed oncology experts.
$35 million extension round led by new investor Colt Ventures and co-led by existing investor OrbiMed with participation from all existing investors
While the biotech put out a press release for its $64 million Series A, led by OrbiMed, it launched without a website and didn’t elaborate on its science beyond “alteration-specific targeted therapies for the treatment of cancer.”
If you missed the news of a new company launch backed by blue-chip investor OrbiMed early Wednesday morning, that was by design. Alterome Therapeutics quietly emerged from stealth with $64 million in its Series A…
Alterome Therapeutics, Inc., a biopharmaceutical company developing alteration-specific targeted therapies for the treatment of cancer, announced the closing of a $64M Series A financing…